Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE (NCT06596252)
Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Who can join: Review the eligibility criteria below.
Location: Dr. Falk Investigational Site — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Dr. Falk Investigational Site — Scottsdale, Arizona
- Dr. Falk Investigational Site — Little Rock, Arkansas
- Dr. Falk Investigational Site — La Jolla, California
- Dr. Falk Investigational Site — San Diego, California
- Dr. Falk Investigational Site — Doral, Florida
- Dr. Falk Investigational Site — New Port Richey, Florida
- Dr. Falk Investigational Site — Boise, Idaho
- Dr. Falk Investigational Site — Boston, Massachusetts
- Wyoming — Ann Arbor, Michigan
- Dr. Falk Investigational Site — Wyoming, Michigan
- Dr. Falk Investigational Site — Rochester, Minnesota
- Dr. Falk Investigational Site — Freehold, New Jersey
- Dr. Falk Investigational Site — New York, New York
- Dr. Falk Investigational Site — Chapel Hill, North Carolina
- Dr. Falk Investigational Site — Cleveland, Ohio
- Dr. Falk Investigational Site — Mentor, Ohio
- Wyoming — Philadelphia, Pennsylvania
- Dr. Falk Investigational Site — Harlingen, Texas
- Dr. Falk Investigational Site — Salt Lake City, Utah
- Dr. Falk Investigational Site — Lynchburg, Virginia
- Department of Gastroenterology, Hospital General de Tomelloso — Tomelloso,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Esophagitis
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis — Phoenix, Arizona
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children — Chicago, Illinois
- A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- Dupilumab for Eosinophilic Esophagitis With Severe Strictures — Chapel Hill, North Carolina
- Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks — Little Rock, Arkansas
Explore by condition: All Eosinophilic Esophagitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.